Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

XBiotech Inc. (XBIT)

$2.30 -0.43% NASDAQ: XBIT · 15-min delayed
  • AUSTIN, Texas
  • Public · NASDAQ: XBIT
  • 87 employees
$69.2MMarket cap
-$45.5MNet income
87Employees
XBITNASDAQ
2015IPO

About XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Reported figures

Financial summary

Net income
-$45.5M
Total assets
$150.1M
Market cap
$69.2M

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Operating income
-$55.7M
Income tax
$235.0K
Net income
-$45.5M
EPS (basic)
$-1.49
EPS (diluted)
$-1.49

Balance sheet

Total assets
$150.1M
Current assets
$127.0M
Total liabilities
$9.7M
Current liabilities
$7.9M
Shareholders’ equity
$140.3M

Cash flow

Operating cash flow
-$39.9M
Investing cash flow
-$289.0K
Financing cash flow
-$10.2M
Net cash flow
-$47.1M

Statements via Polygon.io (SEC filings)

NASDAQ: XBIT
$2.30 -0.43%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$2.12 $3.50

52-week range

Market cap
$69.2M
EPS (diluted)
$-1.49
Shares outstanding
30.1M
Open
Day range
Prev close
Volume
IPO date
Apr 15, 2015

XBiotech Inc. (XBIT) Stock Price

  • Reported a net loss of $45.5M.
  • Trading 34% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review XBiotech Inc..

Write a review
Newsroom

News about XBiotech Inc.

News & sentiment via Polygon.io

FAQ

XBiotech Inc.: frequently asked questions

Is XBiotech Inc. an American company?

XBiotech Inc. is a US-based company headquartered in Austin, Texas, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is XBiotech Inc. headquartered?

XBiotech Inc. is headquartered in Austin, Texas, United States.

Is XBiotech Inc. publicly traded?

Yes — XBiotech Inc. is a publicly traded company. Its stock trades under the ticker symbol XBIT on the NASDAQ.

What does XBiotech Inc. do?

XBiotech Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →